Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2026)

Arcus Biosciences' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $997.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 16.92% year-over-year to $997.0 million; the TTM figure through Mar 2026 stood at $4.2 billion (down 13.71% YoY), while the FY2025 annual figure was $1.1 billion, down 0.96% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $997.0 million, down from $1.1 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.5 billion in Q1 2022, with the low at $974.0 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.2 billion.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 66.07% in 2022, then decreased 25.08% in 2025.
• Arcus Biosciences' Liabilities and Shareholders Equity stood at $1.3 billion in 2022, then dropped by 15.77% to $1.1 billion in 2023, then rose by 5.02% to $1.2 billion in 2024, then declined by 0.96% to $1.1 billion in 2025, then slipped by 12.47% to $997.0 million in 2026.
• Business Quant data shows RCUS's Liabilities and Shareholders Equity at $997.0 million in Q1 2026, $1.1 billion in Q4 2025, and $974.0 million in Q3 2025.